INTRODUCTION {#sec0005}
============

Pharmacotherapy in the elderly is complex and a challenge to health care providers, as up to 77% of older people are affected by multiple chronic diseases \[[@ref001]\]. Polypharmacy associated with multimorbidity increases the risk of adverse drug events (ADE), such as medication-related hospitalizations, and higher health care costs \[[@ref003]\]. The high rates of medication in the elderly and the associated risk for ADE have triggered the development of criteria to identify a potentially inappropriate medication (PIM). Laroche et al. defined PIM as "a drug for which the risk of an ADE outweighs the clinical benefit, particularly when there is evidence in favor of a safer or more effective alternative therapy for the same condition" \[[@ref007]\]. The most well-known PIM list is the American Beers criteria \[[@ref008]\], last updated in 2015 \[[@ref009]\]. Because of the differences in the drug markets between the USA and the European Union, such PIM lists need to be adapted for national use. The German list of PIM for the elderly (Priscus list) was established in line with the international PIM lists \[[@ref007]\] and published in 2010, aiming to reduce the rate of ADE and to provide higher medication safety \[[@ref012]\]. According to previous studies, the prevalence of PIM in the general elderly population in Germany ranged from 20% to 29% \[[@ref013]\]. More than half of the PIMs in the Priscus list are declared as inappropriate for the treatment of people with dementia (PWD) due to side effects in the central nervous system that may worsen cognitive impairment. In addition, adverse effects on the physical functions that reduce the patient's ability to perform everyday tasks \[[@ref012]\]. For instance, long-term exposure to benzodiazepines and anticholinergic medications is associated with an increased risk for drug-induced delirium, a negative influence on cognition, and an increased risk of falls \[[@ref023]\]. Little is known about the prevalence of PIM in community-dwelling PWD in Germany. Our study aims to determine (1) the prevalence of PIM according to the Priscus list in community-dwelling primary care patients who were screened positive for dementia and (2) the sociodemographic and clinical variables associated with the use of PIM.

MATERIALS AND METHODS {#sec0010}
=====================

Study design {#sec0015}
------------

The present cross-sectional analysis is based on data from the DelpHi-MV (Dementia: life- andperson-centered help in Mecklenburg--Western Pomerania) trial, a GP (general practitioner)-based, cluster-randomized, controlled intervention trial to implement and evaluate an innovative concept of collaborative dementia care management in Germany \[[@ref027]\]. Inclusion criteria for the trial were: 70 years or older in age, living at home, screening for probable dementia is positive (DemTect \<9) \[[@ref029]\]. People were systematically screened for these inclusion criteria in participating GP practices. People fulfilling these criteria provided written informed consent for participation. If a patient was unable to give written informed consent, then the form was signed by his or her legal representative (as approved by the Ethical Committee of the Chamber of Physicians of Mecklenburg--Western Pomerania, registry number BB 20/11). All participants were contacted to arrange a baseline assessment at the person's home. Two to four home visits were necessary for the baseline assessment. The comprehensive standardized baseline assessment included a computer-based home medication review (HMR) among other assessments \[[@ref030]\]. The HMR was conducted by Dementia Care Managers (DCM) -- the study-qualified nurses \[[@ref031]\].

Participants {#sec0020}
------------

The present analysis is based on the data of 448 participants who participated in the DelpHi-MV study with a complete baseline medication assessment. [Figure 1](#jad-55-jad160581-g001){ref-type="fig"} shows the CONSORT flow chart of the DelpHi-MV study for the baseline assessment.

Data analyses {#sec0025}
-------------

To analyze the associations between the sociodemographic and clinical variables and the occurrence of PIM variables, the following factors were considered: age, sex, living situation (alone/not alone), cognitive status, functional status, depressive symptoms, visit to a specialist (neurologist/psychiatrist \[yes/no\]), total number of drugs taken, formal diagnosis of dementia, and number of comorbid diagnoses. The severity of cognitive impairment was assessed using the Mini-Mental State Examination (MMSE) \[[@ref032]\]. The severity was categorized as "no indication of cognitive impairment" (score 27--30), "mild" (20--26), "moderate" (10--19), or "severe" (0--9) cognitive impairment \[[@ref033]\]. Depressive symptoms were assessed using the Geriatric Depression Scale (GDS) and categorized as "no depression" (score 0--5) or "possible depression" (score 6--15) \[[@ref034]\]. The functional status was assessed using the Bayer Activities of Daily Living Scale (B-ADL) \[[@ref036]\], which yields a mean score between 1 and 10, where 1 indicates the lowest and 10 the highest possible impairment. In accordance with the International Classification of Diseases and Related Health Problems (ICD-10, German Modification) \[[@ref038]\], medical diagnoses were retrieved from the medical records of the treating GP. A dementia diagnosis refers to any of the following ICD-10 codes: F00/G30 (dementia due to Alzheimer's disease), F01 (vascular dementia), F02 (dementia in other diseases), F03 (unspecified dementia), or G31 (other degenerative diseases of nervous system, not otherwise classified). Diagnosis of mental and behavioral disorders refers to the ICD-10 codes F04-F69. The computer-based home medication anamnesis solicited the study participant's entire medication history (prescription drugs and over-the-counter drugs). Active substances were coded to the Anatomical Therapeutic Chemical (ATC) classification system \[[@ref039]\]. Topical agents and homeopathic and anthroposophic medications were not considered in this analysis.

Identification of PIM {#sec0030}
---------------------

PIMs were identified using the Priscus list \[[@ref012]\]. This German PIM list, which was developed in 2010, takes into account the international PIM lists \[[@ref007]\] and contains 83 active substances from 18 substance classes. The Priscus list contains suggestions for treatment alternatives and measures that should be taken if the respective drug cannot be discontinued (e.g., monitoring laboratory values or dose adjustment). The list names specific diseases for which certain drugs should not be used.

Descriptive statistics {#sec0040}
----------------------

The variables for the patient sample were summarized using descriptive statistics. Metric variables were expressed by means and standard deviation, nominal variables by proportions. For continuous variables, Welch *t*-tests were used in univariate analysis, comparing the individuals with PIM prescription to individuals without PIM, for nominal variables Fisher's exact test was used. Note, that the *p*-values must be treated with care as these tests do not take into account the stochastic dependency of patients who were recruited by the same GP.

Multivariate statistics {#sec0045}
-----------------------

We fitted logistic regression models to evaluate which variables were associated with PIM use which was the dependent variable in these models. The sociodemographic factors (age, sex, living situation) and the total number of drugs were used as covariates and were included to attenuate possible confounding factors, the clinical variables (cognitive status, functional status, depressive symptoms, diagnosis of dementia) were the independent variables of interest. As the clinical variables depend on each other they were tested simultaneously in the described model on significance via a Wald-Test. In a second model, we included the number of diagnosed mental and behavioral disorders (F04-F69) and the number of other comorbidities additionally to the before used variables exploring the effects of these two variables on PIM prescription and the coefficients of the other variables. To account for the clustering of participants who were recruited by the same GP, we applied a conditional (fixed-effect) logistic regression model, which offers consistent estimates of clustered data \[[@ref040]\]. Before running the final regression model, we checked for non-linear relations using the multivariate fractional polynomial procedure \[[@ref042]\]. However, we found no indication of non-linear relationships. The estimation procedure excluded 114 observations because of the invariance in the outcome-variable in the respective clusters (that is, all or none of the patients treated by the same GP received a PIM). We found no significant differences between the included and excluded cases regarding the covariates analyzed (see [Supplementary Table 3](#S1){ref-type="supplementary-material"}), but the frequency of PIM prescription use differed significantly between these groups, as expected. The final regression analysis was performed for the remaining 334 cases belonging to 44 clusters (clusters were unbalanced). The standard errors of the regression coefficients were estimated using the bootstrapping technique with 2000 replications, which provides appropriate estimates of standard errors in complex samples \[[@ref043]\]. Statistical analyses were performed using STATA^®^13 \[[@ref044]\].

RESULTS {#sec0050}
=======

Sociodemographic and clinical characteristics of the study population {#sec0055}
---------------------------------------------------------------------

The sociodemographic and clinical characteristics of the study population are summarized in [Table 1](#jad-55-jad160581-t001){ref-type="table"}.

There were no significant differences regarding age, sex, and the DemTect score among the patients included in the analysis and those who dropped out of the study (see [Supplementary Table 1](#S1){ref-type="supplementary-material"}). Regarding the variables age, Priscus PIMs taken, and sex, there were no significant differences observed between patients included in the analyses and those excluded due to missing data, but the patients not included in the analyses due to missing data had a lower DemTect score than those patients in the baseline analysis (*p* = 0.0001) (see [Supplementary Table 2](#S1){ref-type="supplementary-material"}).

PIM prevalence {#sec0060}
--------------

Of the 448 community-dwelling patients who were screened positive for dementia, a total of 99 study participants (22%) received at least one PIM according to the Priscus list. Ten study participants took 2 PIMs at the same time; one study participant took 3 PIMs. In regard to substances, there were 34 active substances from the Priscus list in 111 cases ([Table 2](#jad-55-jad160581-t002){ref-type="table"}).

The most commonly used active substance classes of PIMs included the following: tricyclic antidepressants (*n* = 25/111; 22.5% of all PIM in our analysis), benzodiazepine derivatives and benzodiazepine-related drugs (*n* = 23/111; 20.7%), nonsteroidal anti-inflammatory and antirheumatic drugs (*n* = 17/111; 15.3%), drugs for urinary frequency and incontinence (*n* = 8/111; 7.2%), and peripherally acting antiadrenergic agents (*n* = 8/111; 7.2%). The most common PIMs were amitriptyline (*n* = 16; 14.4% of all PIMs (111) in our analysis), etoricoxib (*n* = 11/111; 9.9%), doxazosin (*n* = 8/111; 7.2%), diazepam (*n* = 8/111; 7.2%), and solifenacin (*n* = 7/111; 6.3%). None of the study participants in the subgroup taking amitriptyline were diagnosed with neuropathic pain according to the medical records of the treating GP. The remaining active agents from all other drug classes constituted approximately 17% of the prescribed PIMs ([Table 2](#jad-55-jad160581-t002){ref-type="table"}).

Factors associated with PIM use {#sec0065}
-------------------------------

The results of the multivariate conditional fixed-effects logistic regression analyses (*n* = 334 patients assigned to *n* = 44 clusters) are shown in [Tables 3](#jad-55-jad160581-t003){ref-type="table"} and [4](#jad-55-jad160581-t004){ref-type="table"}. The results of the first multivariate conditional logistic regression also showed that the prescription of a PIM was significantly and positively associated with the total number of drugs taken (OR: 1.11; 95% CI: 1.00--1.24; *p* = 0.043) ([Table 3](#jad-55-jad160581-t003){ref-type="table"}). None of the clinical variables (cognitive status, functional status, depressive symptoms, diagnosis of dementia) was significant, neither alone, nor in a Wald-Test, testing all coefficients of these variables simultaneously on zero (chi^2^(4) = 4.01, *p* = 0.4031). The regression model failed to reach a global significance (Wald chi^2^(8) = 11.08, *p* = 0.1971). Therefore, the result regarding the number of drugs taken must be treated carefully. In a second logistic regression model, which included the number of diagnosed mental and behavioral disorders (F04-F69) and the number of comorbidities as additional predictors, the prescription of a PIM was significantly positively associated with a diagnosis of a mental or behavioral disorder (OR: 1.59; 95% CI: 1.10--2.30; *p* = 0.014) ([Table 4](#jad-55-jad160581-t004){ref-type="table"}). Accordingly, the second model reached significance (Wald chi^2^(10) = 22.77, *p* = 0.0116), underlining the predictive value of psychiatric comorbidities for the prescription of a PIM. The association with the total number of drugs taken was no longer significant in the second model, although the effect size was in the same range as that for the first model (OR: 1.13; 95% CI: 0.99--1.30; *p* = 0.070).

DISCUSSION {#sec0070}
==========

PIM in community-dwelling people who were screened positive for dementia {#sec0075}
------------------------------------------------------------------------

Using primary data, we analyzed the prevalence and correlates of PIM prescriptions according to the Priscus list in community-dwelling GP patients who were screened positive for dementia in Germany.Approximately 22% of the patients who were screened positive for dementia received at least one PIM listed in the Priscus list. The prevalence rate of PIM prescriptions in our sample is consistent with the results from previous studies that used the Priscus list and found prevalence rates for PIM use in the general German population (≥65 years of age) between 20% and 29% \[[@ref013]\]. In a prospective multicenter study involving a French cohort of community-dwelling Alzheimer's disease patients (REAL.FR) \[[@ref046]\], the prevalence of PIM prescriptions was 47% according to the Laroche list \[[@ref007]\] but 25% according to the Beers list \[[@ref008]\]. The authors conceded that the prevalence of PIM prescriptions in community-dwelling PWD in France was comparable to that in the elderly population in general. However, because of the differences between the national PIM lists, a direct international comparison of the prevalence of PIM prescriptions with our findings is difficult.

In the AGnES study, which was a community-based, prospective cohort study with home-visit patients, the prevalence of Priscus PIM prescriptions amounted to 27% in the subgroup of patients who were screened positive for dementia \[[@ref045]\]. This prevalence rate is slightly higher compared to that in our results, despite the higher degree of comorbidity in the DelpHi-MV cohort (mean number of 12 compared to 6 comorbid diagnoses per patient). This could be explained by the fact that our data collection started after the publication of the Priscus list, and PIM use in the general population has declined since then.

Tricyclic antidepressants with anticholinergic properties (amitriptyline, trimipramine, doxepin) were the most frequently prescribed PIMs in our analysis (23% of all PIM). This finding is in accordance with a recent Australian study that reported anticholinergics and sedatives as the most commonly prescribed PIM in community-dwelling patients of memory clinics with a diagnosis of mild cognitive impairment or dementia \[[@ref047]\]. Amitriptyline, the most frequent active agent in our analysis (14% of all PIM), is often used to treat neuropathic pain and is inexpensive. This might explain why amitriptyline was the most frequently prescribed PIM in most studies using the Priscus in Germany \[[@ref014]\]. However, none of the study participants using amitriptyline in our analysis had a diagnosis of neuropathic pain by their treating GP in their medical records. It is likely that psychiatric symptoms, such as depressive mood or insomnia, were common reasons for amitriptyline prescriptions in the DelpHi-MV-cohort. At 4% (*n* = 17/448 study participants), the prevalence of benzodiazepine derivatives in our study was lower than that in a previous French study that found an 8.5% prevalence for long-acting benzodiazepines in older people with dementia \[[@ref046]\]. Benzodiazepines (in our sample: diazepam, medazepam, clobazam, chlordiazepoxide, nitrazepam) and benzodiazepine-related drugs (in our sample: zolpidem, zopiclone) are often used in older adults for the treatment of insomnia, depression, or anxiety. In addition, they are used often to treat behavioral symptoms of dementia, despite the lack of evidence for their effectiveness \[[@ref048]\].

In summary, in contrast to guidelines and recommendations \[[@ref033]\], anticholinergics and benzodiazepines were the most common PIM prescriptions in our analysis. This is consistent with previous evidence suggesting that patients with cognitive impairment and dementia have a higher prevalence of anticholinergic and sedative drug prescriptions than matched controls \[[@ref025]\].

Fifteen percent of the prescribed PIMs were anti-inflammatory and antirheumatic substances from the Priscus list (etoricoxib, indometacin, meloxicam, ketoprofen), which are associated with an increased risk of gastrointestinal bleeding, ulceration, or perforation, and renal adverse drug effects \[[@ref012]\]. The PIMs in this group must be carefully interpreted because, in some cases, treatment with these drugs might be the only option for the patient after considering the individual's health status, possible interactions, and other factors.

The present analysis included the complete medication history of the study participants (prescription drugs and over-the-counter drugs). The considerable percentage of over-the-counter drugs is often missing from studies based on secondary (e.g., reimbursement) data alone. The prevalence of over-the-counter PIM (OTC-PIM) was 4.5% for participants who used PIM. OTC-PIMs included the non-prescription hypnotics (doxylamine, diphenhydramine) and antiemetics (dimenhydrinat). These antihistamines for systemic use are also potentially inappropriate for older people owing to their adverse cognitive effects \[[@ref009]\]. Patients or their caregivers rarely inform their GPs about the use of OTC; therefore, it is difficult for physicians to monitor OTC-PIMs and their adverse drug reactions or to estimate their risks of interactions with prescribed medication.

Factors associated with PIM use {#sec0080}
-------------------------------

The results of the multivariate conditional logistic regression analysis showed that the diagnosis of mental or behavioral disorder was significantly associated with PIM use in community-dwelling people who were screened positive for dementia. This can be explained by the fact that many psychotropic substances used to treat mental and behavioral disorders are included in the PIM lists. This is in line with the study of Mann et al. conducted in Austrian nursing home residents, in which neuropsychiatric symptoms were described as a risk factor for PIM use and suggested that neuropsychiatric symptoms rather than cognitive impairments provoked PIM prescriptions \[[@ref051]\]. The severity of cognitive impairment (measured by the MMSE score) was not associated with the risk of taking a Priscus PIM in our analysis. This result agrees with previous German and international studies that also failed to find associations between cognitive impairments or dementia and PIM use \[[@ref049]\].

In contrast, German studies on PIM use in the general population aged over 65 years found that the female sex, age, depression, and the number of drugs taken (polypharmacy) were risk factors for PIM use \[[@ref013]\]. The female sex and polypharmacy were identified as risk factors for PIM use in community-dwelling elders with dementia in Germany, as well as internationally \[[@ref045]\]. In our univariate model, there were equally significant associations between female sex, having a formal diagnosis of dementia, polypharmacy, and PIM use. However, these results were not found in the final multivariate model, thus suggesting confounds by other factors.

Limitations {#sec0085}
-----------

The prevalence of PIM use was analyzed as yes/no, regardless of the frequency of PIM use (regular use or only when required). Because of the data collection method, this analysis could not examine medications in the Priscus list that had dosage specifications. Any dose of a PIM drug was counted as a Priscus PIM (0 for none, 1 for one or more PIMs). Therefore, the PIM prevalence might have been somewhat overestimated in this analysis. Patients who were excluded from the analyses due to missing data had more severe cognitive impairment than the patients that were included, as determined by the DemTect score. This might have biased the results. The PIM prevalence was higher in patients included in the regression analysis compared to those excluded due to invariance in the outcome variables in their respective cluster. Therefore, patients with a lower PIM rate were somewhat under-represented in the regression analysis. Because the DelpHi-MV cohort included mostly patients with mild dementia and just a few patients with severe dementia, the effect of severe dementia on the prescription rates of PIM might have been represented insufficiently. The cognitive screening for identification of dementia can lead to both false negatives (e.g., in more highly educated patients) and false positives (e.g., in less educated patients). The rate of false-positive diagnoses in our study might have been lower than 24% \[[@ref055]\]. That is, the results might have been distorted and should be interpreted with caution.

Conclusion {#sec0090}
----------

The results of the present analyses show that the prevalence of PIM prescriptions in community-dwelling primary care patients who were screened positive for dementia was comparable to the prevalence in the general older population in Germany. The presence of a diagnosis of a mental or behavioral disorder in patients who were screened positive for dementia was the only factor associated with increased PIM use in a multivariate model. Further research should examine whether the presence of a mental/behavioral disorder in people without dementia does have such an impact on PIM in the elderly. Cognitive impairment was not a risk factor for a PIM prescription. Certainly, the individual therapeutic decision of the treating physician may differ from the recommendations of the Priscus list because of other factors that need to be considered, such as the patient's anamnesis, comorbidities, prognostic estimates, individual needs, and prescriptions of co-treating physicians \[[@ref015]\]. Nevertheless, there is a clear potential for an enhanced medication management of PWD, especially regarding drugs with anticholinergic properties and long-acting benzodiazepines for chronic use. Further analysis of our follow-up data will determine the impact of medication management on the reduction of PIM use in community-dwelling primary care patients who were screened positive for dementia.
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###### 

Sociodemographic and clinical characteristics of the study population

                                                                      Total sample       PIM         no PIM       *t*       df         *p*
  ------------------------------------------------------------------ -------------- ------------- ------------- -------- -------- --------------
  Age, mean (SD)                                                      79.9 (5.43)    79.7 (5.51)   79.9 (5.41)   0.327    156.76     0.744^a^
  Sex (female), *n* (%)                                                259 (57.8)     66 (66.7)    193 (55.3)                      **0.050^b^**
  Living situation (living alone), *n* (%)                             222 (49.6)     51 (51.5)    171 (50.0)                        0.733^b^
  Severity of dementia (MMSE), mean (SD)                              22.5 (5.01)    23.3 (4.55)   22.3 (5.12)   --1.83   176.15     0.069^a^
  No cognitive impairment (score, 27--30), *n* (%)                     106 (23.7)     25 (25.3)     81 (23.2)                     
  Mild cognitive impairment (score, 20--26), *n* (%)                   236 (52.7)     56 (56.6)    180 (51.6)                     
  Moderate cognitive impairment (score, 10--19), *n* (%)               97 (21.7)      17 (17.2)     80 (23.0)                     
  Severe cognitive impairment (score, 0--9), *n* (%)                    9 (2.0)        1 (1.0)       8 (2.3)                      
  Diagnosis of dementia (ICD-10: F00-F03/G30/G31), *n* (%)             168 (37.5)     27 (27.3)    141 (40.4)                      **0.019^b^**
  Diagnosis of mental and behavioral disorders (ICD-10:               0.39 (0.79)    0.59 (1.00)   0.33 (0.72)   --2.32   129.00   **0.022^a^**
    F04-F69), mean (SD)                                                                                                           
  Previous visit to specialist (neurologist/psychiatrist), *n* (%)     116 (26.0)     33 (33.3)     83 (23.9)                        0.068^b^
  Total number of drugs, mean (SD)                                     7.2 (3.45)    8.3 (3.06)    6.8 (3.48)    --4.20   178.08   **0.001^a^**
  Comorbid diagnoses, mean (SD)                                       12.1 (7.29)    11.8(6.68)    12.1 (7.46)   0.366    174.92     0.715^a^
  Depression (GDS), *n* (%)                                            72 (15.2)      18 (17.3)     54 (14.6)                        0.238^b^
  Functional status (B-ADL), mean (SD)                                 3.6 (3.37)    3.4 (2.30)    3.6 (2.49)    0.732    169.84     0.465^a^

Standard deviations or percentages are in brackets. MMSE, Mini-Mental State Examination (range 0--30; higher score indicates better cognitive functioning); B-ADL, Bayer Activities of Daily Living Scale (range 0--10; lower score indicates better performance); GDS, Geriatric Depression Scale (sum score 0--15; score ≥6 indicates depression); ^a^Welch's-*t*-test, ^b^Fisher's exact test. Bold *p*-values indicate *p* \< 0.05.

###### 

Potentially inappropriate medication according to Priscus criteria

  Active substance class                                          Active substance                      Study participants using
  --------------------------------------------------------------- ------------------------------------ --------------------------
  Antiinflammatory and antirheumatic products, non-steroids       Indometacin                                   3 (2.7%)
                                                                  Ketoprofen                                    1 (0.9%)
                                                                  Meloxicam                                     2 (1.8%)
                                                                  Etoricoxib                                   11 (9.9%)
  Antiarrhythmics, class IC                                       Flecainide                                    2 (1.8%)
  Cardiac glycosides                                              Acetyldigoxin                                 1 (0.9%)
  Urologicals, Drugs for urinary frequency and incontinence       Solifenacin                                   7 (6.3%)
                                                                  Tolterodine                                   1 (0.9%)
  Tricyclic antidepressants                                       Amitriptyline                                16 (14.4%)
                                                                  Doxepin                                       4 (3.6%)
                                                                  Trimipramine                                  5 (4.5%)
  Antiemetics                                                     Dimenhydrinat                                 2 (1.8%)
  Antihypertensives, Antiadrenergic agents, peripherally acting   Doxazosin                                     8 (7.2%)
  Antihypertensives, Antiadrenergic agents, centrally acting      Clonidine                                     1 (0.9%)
                                                                  Methyldopa                                    3 (2.7%)
  Antipsychotics                                                  Levomepromazine                               1 (0.9%)
                                                                  Haloperidol                                   2 (1.8%)
  Dopaminergic agents                                             Dihydroergocryptine alpha mesilate            1 (0.9%)
  Antidementia drugs                                              Dihydroergotoxine                             1 (0.9%)
  Muscle relaxants, centrally acting agents                       Baclofen                                      3 (2.7%)
                                                                  Tetrazepam^\*^                                1 (0.9%)
  Anxiolytics, Benzodiazepine derivatives                         Diazepam                                      8 (7.2%)
                                                                  Medazepam                                     3 (2.7%)
                                                                  Clobazam                                      1 (0.9%)
                                                                  Chlordiazepoxide                              1 (0.9%)
  Hypnotics and sedatives                                         Chloral hydrate                               1 (0.9%)
  Hypnotics and sedatives, Benzodiazepine derivatives             Nitrazepam                                    3 (2.7%)
  Hypnotics and sedatives, Benzodiazepine related drugs           Zolpidem                                      3 (2.7%)
                                                                  Zopiclone                                     4 (3.6%)
  Antihistamines for systemic use                                 Doxylamine                                    1 (0.9%)
                                                                  Diphenhydramine                               2 (1.8%)
  Psychostimulants, agents used for ADHD and nootropics           Piracetam                                     4 (3.6%)
  Peripheral vasodilators                                         Naftidrofuryl                                 3 (2.7%)
  Beta blocking agents, non-selective                             Sotalol                                       1 (0.9%)

^\*^Suspension of admission in Europe since 1st August, 2013. ^\*\*^Double entry possible.

###### 

Factors associated with PIM use

                                                No PIM          PIM        OR    Bootstrap     z         *p*      95% CI  
  ------------------------------------------ ------------- ------------- ------ ----------- -------- ----------- -------- ------
  Age, mean (SD)                              80.1 (5.62)   79.2 (5.31)   0.96     0.025     --1.54     0.125      0.91    1.01
  Sex (female), *n* (%)                       135 (55.3)     59 (65.6)    1.97     0.718      1.87      0.062     0.966    4.03
  Living situation (living alone), *n* (%)    119 (48.8)     47 (52.2)    1.10     0.39       0.27      0.791      0.55    2.19
  Cognitive impairment (MMSE), mean (SD)      22.4 (5.05)   23.5 (4.18)   1.01     0.033      0.40      0.689      0.95    1.08
  Functional status (B-ADL), mean (SD)        3.5 (2.33)    3.3 (2.27)    1.00     0.086      0.03      0.972      0.85    1.19
  Depression (GDS), *n* (%)                    34 (70.8)     14 (29.2)    1.15     0.506      0.31      0.759      0.48    2.72
  Number of drugs, mean (SD)                  7.0 (3.50)    8.3 (3.15)    1.11     0.060      2.02    **0.043**    1.00    1.24
  Dementia diagnosis, *n* (%)                 102 (41.8)     23 (25.6)    0.58     0.237     --1.33     0.183      0.26    1.29

Multivariate conditional fixed-effects logistic regression analysis (*n* = 334 patients assigned to *n* = 44 clusters): Wald chi^2^(8) = 11.08, *p* = 0.1971. Data presented as mean±standard deviation or *n* (%). OR, odds ratio; CI, confidence interval; MMSE, Mini-Mental State Examination (range 0--30; higher score indicates better cognitive functioning); B-ADL, Bayer Activities of Daily Living Scale (range 0--10; lower score indicates better performance); GDS, Geriatric Depression Scale (sum score 0--15; score ≥6 indicates depression). Bold *p*-values indicate *p* \< 0.05.

###### 

Factors associated with PIM use, considering of diagnosis of mental and behavioral disorders and other comorbid diagnoses

                                                    No PIM          PIM        OR    Bootstrap     z         *p*      95% CI  
  ---------------------------------------------- ------------- ------------- ------ ----------- -------- ----------- -------- ------
  Age, mean (SD)                                  80.1 (5.62)   79.2 (5.31)   0.98     0.027     --1.21     0.228      0.92    1.02
  Sex (female), *n* (%)                           135 (55.3)     59 (65.6)    1.78     0.707      1.46      0.145      0.82    3.88
  Living situation (living alone), *n* (%)        119 (48.8)     47 (52.2)    1.09     0.406      0.23      0.814      0.53    2.26
  Cognitive impairment (MMSE), mean (SD)          22.4 (5.05)   23.5 (4.18)   1.02     0.035      0.71      0.480      0.96    1.10
  Functional status (B-ADL), mean (SD)            3.5 (2.33)    3.3 (2.27)    1.00     0.091     --0.02     0.984      0.84    1.19
  Depression (GDS), *n* (%)                        34 (70.8)     14 (29.2)    1.22     0.540      0.44      0.660      0.51    2.90
  Number of drugs, mean (SD)                      7.0 (3.50)    8.3 (3.15)    1.13     0.080      1.77      0.077      0.99    1.30
  Dementia diagnosis, *n* (%)                     102 (41.8)     23 (25.6)    0.59     0.234     --1.34     0.181      0.27    1.28
  Diagnosis of mental and behavioral disorders     0.3 (0.7)     0.6 (1.0)    1.59     0.300      2.47    **0.014**    1.10    2.30
    (ICD-10: F04-F69), mean (SD)                                                                                              
  Comorbid diagnoses, mean (SD)                   12.4 (7.2)    12.4 (6.7)    0.96    0.0367     --1.00     0.316      0.89    1.04

Multivariate conditional fixed-effects logistic regression analysis (*n* = 334 patients assigned to *n* = 44 clusters): Wald chi^2^(10) = 22.77, *p* = 0.0116. Data presented as mean±standard deviation or *n* (%). OR, odds ratio; CI, confidence interval; MMSE, Mini-Mental State Examination (range 0--30; higher score indicates better cognitive functioning); B-ADL, Bayer Activities of Daily Living Scale (range 0--10; lower score indicates better performance); GDS, Geriatric Depression Scale (sum score 0--15; score ≥6 indicates depression). Bold *p*-values indicate *p* \< 0.05.
